Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF

被引:96
作者
Lang, Alois H. [1 ,2 ]
Drexel, Heinz [1 ,2 ,3 ,4 ]
Geller-Rhomberg, Simone [1 ,3 ]
Stark, Nicole [1 ,3 ]
Winder, Thomas [1 ,2 ,3 ]
Geiger, Kathrin [1 ,3 ]
Muendlein, Axel [1 ,3 ]
机构
[1] Vorarlberg Inst Vasc Invest & Treatment, A-6807 Feldkirch, Austria
[2] Acad Teaching Hosp Feldkirch, Dept Med & Cardiol, Feldkirch, Austria
[3] Private Univ Principal Liechtenstein, Triesen, Liechtenstein
[4] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
关键词
METASTATIC COLORECTAL-CANCER; K-RAS MUTATIONS; POINT MUTATION; AMPLIFICATION; CETUXIMAB; PANITUMUMAB; SYSTEM; V600E; GENE; ARMS;
D O I
10.1016/j.jmoldx.2010.11.007
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mutations in the oncogenes KRAS and BRAF have been identified as prognostic factors in patients with colorectal diseases and as predictors of negative outcome in epidermal growth factor receptor-targeted therapies. Therefore, accurate mutation detection in both genes, KRAS and BRAF, is of increasing clinical relevance. We aimed at optimizing allele-specific real-time PCR assays for the detection of common mutations in KRAS and the BRAF Val600Glu mutation using allele-specific PCR primers for allelic discrimination and probes (TaqMan) for quantification. Each reaction mix contains a co-amplified internal control to exclude false-negative results. Allele-specific real-time PCR assays were evaluated on plasmid model systems providing a mutation detection limit of 10 copies of mutant DNA in proportions as low as 1% of the total DNA. Furthermore, we analyzed 125 DNA samples prepared from archived, formalin-fixed, paraffin-embedded colorectal carcinomas and compared results with those obtained from direct-sequence analysis. All mutations determined by sequence analysis could be recovered by allele-specific PCR assays. In addition, allele-specific PCR assays clearly identified three additional samples affected by a mutation. We propose these allele-specific real-time PCR assays as a low-cost and fast diagnostic tool for accurate detection of KRAS and BRAF mutations that can be applied to clinical samples. (J Mol Diagn: 2011, 13: 23-28; DOI: 10.1016/j.jmoldx.2010.11.007)
引用
收藏
页码:23 / 28
页数:6
相关论文
共 21 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]   Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[3]   Multiplexed assays for detection of mutations in PIK3CA [J].
Board, Ruth E. ;
Thelwell, Nicola J. ;
Ravetto, Paul F. ;
Little, Stephen ;
Ranson, Malcolm ;
Dive, Caro-Line ;
Hughes, Andrw ;
Whitcombe, David .
CLINICAL CHEMISTRY, 2008, 54 (04) :757-760
[4]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[5]  
Clayton SJ, 2000, CLIN CHEM, V46, P1929
[6]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[7]   Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].
Di Nicolantonio, Federica ;
Martini, Miriam ;
Molinari, Francesca ;
Sartore-Bianchi, Andrea ;
Arena, Sabrina ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Mazzucchelli, Luca ;
Frattini, Milo ;
Siena, Salvatore ;
Bardelli, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712
[8]   High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies [J].
Do, Hongdo ;
Krypuy, Michael ;
Mitchell, Paul L. ;
Fox, Stephen B. ;
Dobrovic, Alexander .
BMC CANCER, 2008, 8 (1)
[9]   Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues [J].
Dufort, Sandrine ;
Richard, Marie-Jeanne ;
de Fraipont, Florence .
ANALYTICAL BIOCHEMISTRY, 2009, 391 (02) :166-168
[10]   The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system [J].
Fox, JC ;
England, J ;
White, P ;
Ellison, G ;
Callaghan, K ;
Charlesworth, NR ;
Hehir, J ;
McCarthy, TL ;
Smith-Ravin, J ;
Talbot, IC ;
Snary, D ;
Northover, JMA ;
Newton, CR ;
Little, S .
BRITISH JOURNAL OF CANCER, 1998, 77 (08) :1267-1274